Interestingly, the same study reported that CD133+ CRC cells form less aggressive tumors, which is supported by recent clinical studies where strong CD133 expression, as determined by immunohistochemistry, is associated with longer progression-free survival in patients with metastatic CRC [49, 50]. Here, PROM1 is linked to colorectal carcinoma.